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The prion gene family currently consists of three members: Prnp which encodes PrPC, the precursor to prion disease associated isoforms such
as PrPSc; Prnd which encodes Doppel, a testis-specific protein involved in the male reproductive system; and Sprn which encodes the newest PrP-
like protein, Shadoo, which is expressed in the CNS. Although the identification of numerous candidate binding partners for PrPC has hinted at
possible cellular roles, molecular interpretations of PrPC activity remain obscure and no widely-accepted view as to PrPC function has emerged.
Nonetheless, studies into the functional interrelationships of prion proteins have revealed an interesting phenomenon: Doppel is neurotoxic to
cerebellar cells in a manner which can be blocked by either PrPC or Shadoo. Further examination of this paradigm may help to shed light on two
prominent unanswered questions in prion biology: the functional role of PrPC and the neurotoxic pathways initiated by PrPSc in prion disease.
© 2007 Elsevier B.V. All rights reserved.Keywords: Prion; PrP; Doppel; Shadoo; Neurodegenerative disease; Transgenic mice; Knockout mice; Binding partners; Neurotoxicity1. Introduction
Prions are infectious proteins which are formed by virtue of a
conformational change involving PrPC, the cellular prion
protein, into a disease-associated conformer termed PrPSc.
According to the protein-only hypothesis [1], PrPSc is the sole
component of the infectious particle and replicates by recruiting
molecules of PrPC and templating their conversion into
additional PrPSc molecules. Naturally occurring prion diseases
have been described in humans (with either genetic or sporadic
etiologies) and in sheep and goats, but it is the ‘artificially-
induced’ prion diseases such as bovine spongiform encephalo-
pathy (BSE) and variant Creutzfeldt–Jakob Disease (vCJD)
which have put prions into the media spotlight. The spectrum of
prion diseases is increasing with emergent prion diseases
representing an unknown but worrying risk to human health,
particularly in the case of chronic wasting disease (CWD) [2,3].⁎ Corresponding author. Alberta Centre for Prions and Protein Folding
Diseases, Room 116, Environmental Engineering Building, University of
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doi:10.1016/j.bbadis.2007.05.001Consequently, the majority of prion research (and perhaps
rightly so) has focused on understanding the biochemistry of
PrPSc, the disease-associated conformational transition, and the
transmission properties of prions. In contrast, despite consider-
able effort, relatively little is known about PrPC, the benign
precursor to PrPSc, which is present in the brains and other
tissues of healthy individuals.
Although mice lacking the prion protein (PrP) have been
available for more than a decade, the function of PrPC remains a
mystery [4,5]. The knockout mice are resistant to prion disease
and do not propagate infectious prions, confirming the absolute
requirement of PrPC for the prion disease process [6,7], but
otherwise live normal healthy lives with only subtle or disputed
phenotypic abnormalities under resting conditions [8–13] (see
below). Clearly PrPC must possess some beneficial attribute
since it is well conserved amongst various species and it is
implausible that evolutionary pressure would have acted on
PrPC for the sole reason of conferring susceptibility to prion
diseases [14]. Deciphering the enigmatic function of cellular
PrP may be instructive for the following reasons: (1) The
pathogenic mechanisms underlying prion disease are poorly
understood and may involve subversion of PrPC function. (2)
Some therapeutic strategies for prion disease involving down-
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neuroprotective activity. (3) Unmasking the function of PrPC
may provide a more complete understanding of neuronal
physiology.
Another avenue of research into the biology of PrPC has
recently been opened up with the discovery of two paralogs.
The first, Doppel, is a testis-expressed protein which appears to
have a critical role in the proper functioning of the male
reproductive system [15,16]. The second, Shadoo, is a CNS-
expressed protein which has many similar properties with PrPC
and may possess an overlapping activity [17]. Functional
interactions between the three prion proteins are capable of
modulating the degeneration of cerebellar cells in culture or in
transgenic mice with Doppel possessing an opposing function-
ality to either PrPC or Shadoo. A careful examination of these
PrPC-related proteins within the context of this particular
paradigm may shed light onto the enigmatic function of PrPC
(and perhaps on disease mechanisms related to PrPSc).
This review focuses on several aspects of prion physiology
involving PrPC, Doppel, and Shadoo. The genetics, biochem-
istry, and cell biology of the three prion proteins are discussed,
as well as recent data on the quest to decipher their functional
activities and interacting partners.
2. The three prion genes (and PRNT)
2.1. PRNP
The genes encoding the human, hamster, and mouse prion
proteins were first cloned in 1986 [18–21]. The Prnp gene is
located on chromosome 2 in mice and PRNP is on chromosome
20 in humans. Both genes consist of three exons with the entire
open reading frame located in exon 3 (Fig. 1). Polymorphisms
in both human and mouse prion genes have been described with
the codon 129 polymorphism in PRNP being a critical
determinant of human prion disease susceptibility. For instance,
no individuals with the V129 allele have contracted vCJD thusFig. 1. Schematic structural representation of the mouse genes encoding the PrP, Dopp
Prnd genes encoding the PrP and Doppel proteins, respectively. The Sprn gene enco
mice, the splice acceptor site of Prnp exon 3 is deleted resulting in the production of c
mRNA generated is shown.far suggesting that V129 prevents vCJD prion infection [22].
This phenomenon has now been modeled in transgenic mice
with numerous interesting conclusions with relevance to human
health [23,24]. Several mutations in PRNP are known to cause
genetic CJD (now referred to as gCJD, previously termed
familial CJD or fCJD) including D178N (which causes either
gCJD or fatal familial insomnia, depending on the residue in cis
at codon 129), E200K (which causes gCJD), and P102L (which
causes Gerstmann–Sträussler–Scheinker syndrome) [25,26].
As noted, genetic ablation of Prnp in mice causes no spectacular
phenotypes (see below) other than conferring resistance to prion
disease [6].
2.2. PRND
The discovery of the gene encoding the Doppel protein came
about in a rather indirect manner. While the earliest strains of
Prnp0/0 mice exhibited no phenotypic abnormalities [4,8], some
strains exhibited late-onset ataxia characterized by loss of
Purkinje cells in the cerebellum (see below) [27,28]. Initially,
these results were interpreted in favour of a role for PrPC in the
long-term survival of Purkinje cells. However, upon closer
examination, it became apparent that the phenotypic effect
resulted from an artifact of the genetic engineering used in
ataxia-prone Prnp0/0 mice. A previously unappreciated gene
lying 16 kb downstream of the murine Prnp locus was dis-
covered as a result of an extensive sequencing effort [15]. The
gene, dubbed Prnd, contained an open reading frame encoding
the Doppel protein. Strains of Prnp0/0 mice in which the splice
acceptor site of exon 3 of the Prnp gene has been removed
result in the production of chimeric Prnp/Prnd mRNAs
(essentially putting the Prnd gene under the control of the
Prnp promoter) and permitting the Doppel protein (whose post-
embryonic expression is principally confined to the testis) to be
expressed in the CNS (Fig. 1). Bovine Doppel expression has
also been observed in circulating lymphoid cells, in B-cells,
neutrophils, and in follicular dendritic cells within lymphoidel, and Shadoo proteins. The Prn locus on chromosome 2 contains the Prnp and
ding the Shadoo protein is found on chromosome 7. In ataxic strains of Prnp0/0
himeric Prnp/PrndmRNAs. The exonic structure of the most abundant chimeric
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human PRND gene (both within the coding sequence and in the
untranslated regions) and there is debate as to whether or not
these confer risk for sporadic CJD [31–33]. The functional
consequences of PRND polymorphisms have not yet been fully
explored, although they are known not to alter Doppel ex-
pression or trafficking in tissue culture [34].
2.3. SPRN
The third member of the prion gene family was sighted in a
search of publicly-available databases for nucleotide sequences
with similarity to the Prnp sequence. One such “hit” was for a
cDNA predicted to encode a short protein which had similarity
to the alanine- and valine-rich central hydrophobic region of
PrP. The protein was coined Shadoo (supposedly the Japanese
word for ‘shadow’) and the gene was termed Sprn (for ‘shadow’
of the prion protein) [17]. Sprn seems to be widely conserved in
nature, being present in the genomes of lower organisms such as
zebrafish all the way up to rodents and primates. Sprn is not part
of the Prn genomic locus (containing Prnp and Prnd) and
instead can be found on chromosomes 7 and 10 in mice and
humans, respectively. Like Prnp and Prnd, the entire open
reading frame of Sprn is contained within a single exon (Fig. 1).
Analysis of expression patterns implies that Sprn expression is
restricted to the brain, suggesting that unlike Doppel, the
Shadoo (Sho) protein may be pertinent to prion-associated CNS
phenomena. Mammalian genomes have a single Sprn gene,
whereas two zebrafish genes have been noted (the Sprna and
Sprnb genes encoding the Sho-1 and Sho-2 proteins, respec-
tively). Bioinformatic analysis of Sprn and Prnp sequences
from diverse organisms has suggested that the primeval prion
protein gene may have been related to Sprn, with the Prnp and
Prnd genes evolving later [35].Fig. 2. Schematic representation of the domain architecture of the prion protein family
of 3 α-helices and 2 short β-strands as well as basically-charged N-terminal regions.
sites (CHO) are denoted below the proteins. Repetitive regions are found in both PrP
and the latter possessing tetrarepeats rich in arginine and glycine residues. Awell-con
residues defining the N- and C-termini of ‘ΔPrP’ deletions (Δ32–121 and Δ32–132.4. PRNT
A hypothetical fourth prion gene has been described in the
form of PRNT, a sequence found in the same genomic cluster as
human PRNP and PRND (situated approximately 3 kb down-
stream of PRND) [36]. PRNT exists as three distinct splicing
isoforms with the corresponding predicted amino acid sequences
lacking any distinctive homology to either PrPC or Doppel.
Further work has shown that PRNT is not present in rodents [35]
and that its existence may be restricted to primate species [37].
Expression appears to be limited to the testis, the major site of
Doppel protein expression [36]. No evidence has been tendered
concerning the existence of the predicted 94 residue protein
encoded by the open reading frame and it is currently unclear as
to whether PRNT even comprises a bona fide gene in humans.
3. Structure of prion and prion-like proteins
PrPC is synthesized with N- and C-terminal signal
sequences, the former targeting it to the endoplasmic reticulum
(although not with perfect efficiency which may lead to the
generation of small amounts of cytoplasmic PrP [38]) and the
secretory pathway and the latter directing removal of a C-
terminal signal peptide (followed by the addition of a GPI
anchor, which tethers PrPC to the outer leaflet of the plasma
membrane) [39]. As is common with GPI-anchored proteins,
PrPC is found in cholesterol-rich lipid raft domains within the
membrane [40]. PrPC contains two consensus sequences for N-
linked glycosylation and un-, mono-, and di-glycosylated
versions of PrPC are simultaneously present in the cell. The
structures of PrPC from various species have been determined
and are remarkably similar: the N-terminus is unstructured in
solution whereas the C-terminal domain consists of a three α-
helix bundle with two short β-strands (Fig. 2a) [41–44]. Subtlemembers. Both Doppel and PrPC have structured C-terminal domains consisting
Disulfide bridges are indicated above the proteins (–S–S–) and N-glycosylation
C and Shadoo with the former possessing octarepeats capable of binding copper
served hydrophobic tract is also illustrated in PrPC and Shadoo. The locations of
4) are also noted for PrPC.
657J.C. Watts, D. Westaway / Biochimica et Biophysica Acta 1772 (2007) 654–672differences exist amongst structures from various species
including elk PrPC which possesses a well-defined loop
between β-sheet 2 and α-helix 2, a region which is disordered
in other species [45]. A single disulfide bond is present in the
PrPC C-terminal domain linking together cysteine residues
present in helices B and C. Other features of the cellular prion
protein include an N-terminal octarepeat region consisting of
five repeats of the sequence PHGGGWGQ in the case of
human PrPC. The octarepeat region is notable for several
reasons. Firstly, the histidine residues are capable of binding
copper with four copper-binding sites located within the
octarepeat region [46,47] and copper is known to induce
endocytosis of PrPC [48,49]. Secondly, expansions of the
octarepeat domain (with up to thirteen total repeats) are known
to cause genetic prion disease classified as either gCJD or GSS
[50] and expression of this 14 octarepeat mutant protein in
transgenic mice causes a non-transmissible neurological
syndrome [51]. The second notable region is the hydrophobic
tract prior to the beginning of the structured domain. This
sequence is well conserved amongst PrPC sequences from a
variety of species. Mutations within this sequence can increase
the formation of CtmPrP (a transmembrane topological variant
of PrP in which the C-terminus is lumenal and the N-terminus
is cytoplasmic) which has been linked to neurodegeneration
[52,53]. Furthermore, as N-terminal deletions in PrPC invade
this domain, the truncated proteins become increasingly toxic
to transgenic mice (see below) [54]. The extreme N-terminus
of PrP (the basically-charged region beginning at residue 23 of
mouse PrP) is also important for its proper trafficking in the
cell [55,56]. Upon suramin-induced misfolding of PrPC,
constructs lacking this region remain on the cell surface,
indicating a defect in the trafficking and recycling of misfolded
proteins [57].
The tertiary structure of Doppel is very similar to the C-
terminal domain of PrPC, even though their C-terminal domains
only share approximately 25% sequence identity at the amino
acid level. The structures of human and mouse recombinant
Doppel have been solved by NMR and are very similar, both
consisting of a globular fold with the same secondary structural
elements as PrPC [58,59]. Notable differences to PrPC include a
disruption in helix B separating it into B and B′ regions and
generating a ‘kinked’ helix, a different orientation of the two β-
strands, and an additional outer disulfide bond (Fig. 2b). Like
PrPC, Doppel migrates through the secretory pathway where its
N-terminal signal sequence is removed, its C-terminal signal
sequence replaced with a GPI anchor, and it is modified by the
addition of N-linked sugars at asparagine residues 99 and 111
(mouse gene residue numbering) and possibly O-linked
carbohydrate moieties at threonine residue 43 (human gene
residue numbering), although the latter may be restricted to
human Doppel as Thr43 is not conserved in mouse [34,60].
Like PrPC, Doppel localizes to lipid rafts in the testis of wild-
type mice [61]. The extreme N-terminus of Doppel is flexibly
disordered and positively charged like that of PrPC and likely
contributes to its proper trafficking. Fusion of the Doppel N-
terminus to PrP lacking its N-terminus and octarepeats restores
wild-type trafficking properties [57]. In short, Doppel resemblesthe C-terminal domain of PrPC but lacks the N-terminal
hydrophobic and octarepeat regions.
Murine Shadoo is predicted to be a 98 residue protein with
N- and C-terminal signal sequences mirroring those in PrPC and
Doppel (Fig. 2c) [17]. N-glycosylation is also conserved, but is
only predicted to occur at a single site. The overall architecture
of Shadoo is reminiscent of the N-terminal half of PrPC and thus
stands in stark contrast to Doppel, which shares homology to
the PrPC C-terminal domain. Although Shadoo lacks the
octarepeat sequences found in PrPC, it does have a series of
N-terminal charged tetrarepeats rich in glycine, serine, alanine
and arginine. As mentioned, the bulk of the homology between
Shadoo and PrPC is found within the hydrophobic tract.
Notably, this is one of the most conserved regions amongst PrP
sequences from diverse organisms, perhaps implying functional
homology. Shadoo protein appears to lack any discernible
elements of secondary structure (at least by bioinformatic
analyses), in concordance with its homology to the unstructured
N-terminus of PrPC. The Shadoo region analogous to the α-
helical domain present in PrPC and Doppel is shorter, and is not
long enough to accommodate three α-helices. Additionally,
Shadoo is devoid of cysteine residues, preventing the formation
of stabilizing disulfide bridges. Thus, the C-terminal domain of
Shadoo is unique within the prion protein family and is likely to
be unstructured. Recent studies have provided the first evidence
for the existence of Shadoo protein in the mouse brain. Murine
Shadoo is a GPI-anchored cell-surface glycoprotein which
undergoes endoproteolysis in a manner reminiscent of PrPC
(JCWand DW, in revision). Expression of Shadoo in the mouse
brain is less widespread than PrPC and is prominent in two
regions in which PrPC is notably absent: the Purkinje cells in the
cerebellum and the dendritic processes of hippocampal
pyramidal cells. This suggests that Shadoo could provide a
PrPC-like function to areas of the brain naturally deficient in
PrPC. Additionally, Shadoo can exhibit functional redundancy
with PrPC (see below) supporting its candidacy as the ‘third’
cellular prion protein. A separate study has also shown that an
epitope-tagged cDNA encoding the zebrafish Sho-2 protein
generates an N-glycosylated, GPI-anchored cell-surface protein
when expressed in mammalian cells [62].
4. Functions of prion proteins
Although the lack of spectacular phenotypes in Prnp0/0 mice
has hindered deciphering the function of PrPC, several more
subtle phenotypes have provided clues towards its physiological
role. Unfortunately, repetition of some of these phenotypes has
proven challenging suggesting the possibility of confounding
variables such as differences in genetic background. The first
phenotype reported in Prnp0/0 mice was a defect in synaptic
function in the form of impaired GABA receptor-mediated fast
inhibition and long term potentiation in hippocampal CA1
pyramidal neurons [10]. These synaptic defects were later
shown to be rescued by introduction of a wild-type human PrP-
overexpressing transgene but not a transgene with only
moderate PrP expression [63]. In contrast, another group was
unable to observe any defects in synaptic transmission in the
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Purkinje cell synaptic transmission was found in Prnp0/0 mice
[64]. Other changes which have been observed in the
hippocampus of Prnp0/0 mice include disrupted Ca2+-activated
K+ currents and reorganization of mossy fibres [65,66].
Electrophysiological defects (reductions in after hyperpolariza-
tion potentials in CA1 neurons) have also been observed in mice
in which the Prnp gene has been ablated post-natally [67].
Another phenotype which has been noted in Prnp0/0 mice is an
alteration in circadian activity rhythms and sleep patterns [9].
Notably, this is true for two independent knockout strains (with
different gene-targeting strategies) and suggests that the
behavioural alterations in the human prion disease fatal familial
insomnia (and perhaps sleep–wake disturbances in sporadic
CJD [68]) may be due in part to a loss of PrPC function.
Surprisingly, this phenomenon remains relatively unexplored
although one group has found that PrP mRNA levels in the rat
forebrain are regulated in a circadian manner [69].
A recent publication has documented a learning impairment
in Prnp0/0 mice with defects in hippocampal-dependent spatial
learning and reduction in long-term potentiation in the dentate
gyrus [70]. These defects could be rescued by introduction of a
wild-type PrP transgene under the control of the neuron-specific
enolase promoter and were independent of the genetic back-
ground of the mice. Impairments to long- and short-term
memory retention have also been observed in 9 months old (but
not 3 months old) Prnp0/0 mice [71,72]. In contrast, other
studies have failed to find any overt changes to learning or
behaviour in Prnp0/0 mice [72,73].
In part because PrPC is capable of binding copper in vivo
[47], it has been proposed that PrPC may function as a
superoxide dismutase (SOD). Cu2+-bound SOD is involved in
the detoxification of damaging superoxide radicals by convert-
ing them to oxygen and hydrogen peroxide. Decreased Cu/Zn
SOD activity has been observed in brain homogenates prepared
from Prnp0/0 mice [12] or Prnp+/+ brain homogenates which
have been immuno-depleted of PrPC [74], and this phenomenon
may be caused by an ability of PrPC to regulate the incorporation
of Cu2+ into SOD [75]. Alternatively, PrPC may possess some
intrinsic SOD activity [76], although another group has failed to
find any SOD-1 activity in recombinant PrP [77]. The ability of
PrPC to regulate SOD activity remains contentious as multiple
groups have reported that changes in Prnp gene dosage do not
affect SOD1 or SOD2 activity levels in vivo [13,78].
Two recent papers have begun to unravel subtle roles for
PrPC in the development of the nervous and hematopoietic
systems. One study has focused on the effect of PrPC expression
levels on the developing nervous system [79]. The authors find
that PrPC increases neuronal differentiation in the dentate gyrus
in vitro (i.e. the lowest amount of differentiation is observed in
Prnp0/0 mice) and increases cellular proliferation in the
subventricular zone in vivo. However, adult mice, regardless
of PrP genotype, have the same number of mature neurons
suggesting that factors other than PrPC contribute to the
development of the nervous system. In the second study the
authors show that hematopoietic stem cells (HSCs) isolated
from the bone marrow of Prnp0/0 mice were impaired in theirability to self-renew following reconstitution of irradiated mice
and that this defect could be repaired by introduction of PrPC
into cells by retroviral infection [80]. These results point to a
role for PrPC in the long-term maintenance of HSCs but fail to
enlighten as to why the predominant site of PrPC expression is
in the adult CNS.
Of the several proposed cellular functions for PrPC, none
have been described in molecular terms. One broadly accepted
observation concerns a role for PrPC in neuroprotection against
pro-apoptotic stimuli. For example, PrPC is capable of
protecting cerebellar cells from Doppel-induced neurodegen-
eration (discussed below) and engagement of PrPC through the
use of a PrPC-binding peptide is capable of preventing
anisomycin-induced death in rodent retinal explants [81]. Addi-
tionally, PrPC over-expression in human neurons appears to
counteract the toxic actions of Bax expression [82]. The pro-
tective activity of PrPC is dependent on the presence of the
octarepeat region but interestingly is not lost when PrPC lacking
its GPI anchor (i.e. secreted PrPC) is used. This phenomenon
also has a parallel in yeast–here mammalian PrPC specifically
engineered to enter the yeast secretory pathway is capable of
blocking Bax toxicity [83]. In this paradigm, however, the
octarepeats are not absolutely required and a deletion of
residues 23–31 blunts protective ability (a similar deletion in
PrPC also abrogates its ability to protect against Doppel and is
likely due to a deletion-induced defect in PrP-trafficking [84]).
In both paradigms, cell-surface localization of PrPC (or at least
proper transport through the secretory pathway) is required for
protection. A molecular interpretation of this activity remains
unclear, although a signaling event from the extracellular milieu
may be involved since cell-surface PrPC is capable of blocking a
cytotoxic event occurring in the cytoplasm. Another example of
the neuroprotective activity of PrPC is found in its influence on
stroke biology. PrPC expression is up-regulated following
ischemic brain damage, in both humans and mice [85,86].
Furthermore, PrPC deficiency in mice increases infarct size
following cerebral artery occlusion and increases caspase-3
activation [87], and PrPC overexpression improves neurological
behaviour and reduces infarct volume in a rat stroke model [88].
Paradoxically, pro-apoptotic activities of PrPC have also been
observed. Antibody-mediated crosslinking of PrPC in vivo
causes death of both hippocampal and cerebellar cells although
this pro-apoptotic activity may be limited to dimerized PrPC
[89]. Additionally, it has been shown that PrPC over-expression
in HEK293 cells can enhance staurosporine-induced toxicity
and activation of caspase-3 [90] and that over-expression in
TSM1 cells can sensitize neurons to apoptotic stimuli via
regulation of a p53-dependent caspase-3 activation [91].
In contrast to PrPC, more definitive clues concerning the
function of Doppel have been uncovered. As mentioned,
although Doppel is present at low levels in the brain during
embryonic development and neonatal life, expression in adults
is most evident in the testis (and to a lesser extent in the heart)
[15,92]. Doppel immunoreactivity is present in both somatic
and germ cells of the male reproductive tract including
ejaculated spermatozoa, seminal plasma, seminiferous tubules,
Sertoli cells, and the acrosome, with possible species-specific
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Therefore, it is not surprising that Doppel knockout mice suffer
from a reproductive defect. Males from two published lines of
Doppel knockout (Prnd0/0) mice are sterile, suggesting that
Doppel plays a role in the normal functioning of the re-
productive system [16,95]. In both lines, mating behaviour is
unaltered and mice are capable of ejaculation, implying a
specific defect in the development of sperm. The sperm from
one line are reduced in number and exhibit reduced motility and
morphological defects, but this was not confirmed in the second
line, possibly due to differences in genetic background. In the
first line, mutant sperm are unable to initiate fertilization in vitro
unless the zona pellucida is mechanically dissected. In vitro
fertilization is possible in the second line, albeit at a reduced
rate. Embryos fertilized by Doppel-deficient sperm are unable
to progress past the morula stage which the authors attribute to
an increase in DNA damage in the sperm. Sperm from both
lines appear to be incapable of undergoing a proper acrosome
reaction, either preventing or impeding fertilization in vitro. A
mechanism-based interpretation of these events has not yet been
described. It seems unlikely that Doppel and PrPC have
functional overlap since no reproductive defects have been
observed in Prnp0/0 mice. Perhaps the CNS-specific role(s) of
PrPC are dependent on the domains not present in Doppel (i.e.
the octarepeats and the hydrophobic tract). Interestingly, a
truncated Doppel-like form of PrPC is the most prominent PrP
species in the testis [34] suggesting that truncated PrPC and
Doppel may have overlaps in function within the testis. In
contrast to Prnd0/0 mice, transgenic mice (accidentally) over-
expressing ovine Doppel under the control of its endogenous
promoter did not exhibit any alterations in reproductive
behaviour [96].
No defects in the development or maintenance of the central
nervous system (CNS) or other tissues were observed in either
Prnd0/0 or Prnp0/0/Prnd0/0 double knockout mice implying that
like PrPC, Doppel is dispensable in the brain (which is not
surprising since its expression in the brain is minimal in post-
embryonic stages) and that the lack of a phenotype in Prnp0/0
mice is not a result of functional compensation by Doppel [95].
Several studies have shown that like PrPC Doppel is capable
of binding copper. This likely involves histidine residue 131 of
the mouse sequence which is within the αB/B′-loop-αC region
which stands in marked contrast to the octarepeat copper
binding sites in PrPC [97]. The physiological implications of
copper binding may be different for the two proteins as PrPC
can bind more equivalents of copper and therefore may be more
suited as a copper scavenger. Additionally, in contrast to PrPC,
no internalization of Doppel is observed following copper
binding [98]. One study has reported that detergent-extracted
Doppel from mouse testis does not bind to an immobilized
metal affinity column loaded with copper leading to the
suggestion that Doppel is not capable of binding copper or is
perhaps already metallated [61].
The physiological function of Shadoo in the CNS is
unknown and evaluating Sprn knockout (and perhaps Sprn/
Prnp double knockout) mice may help to clarify its role. In
cerebellar granule cells isolated from Prnp0/0 mice Shadoo, likePrPC, is able to abrogate Doppel-induced toxicity suggesting
that PrPC and Shadoo may possess overlapping functions
related to neuroprotection (JCW and DW, in revision). This
function seems to be dependent on the presence of an intact
hydrophobic tract (the highest region of conservation between
the two proteins) since removal of the domain in either protein
abolishes their neuroprotective capabilities. Additionally, the
partially reciprocal pattern of expression of Shadoo and PrPC in
the CNS suggests that they could provide a common function to
neuronal cells.
5. Prion protein ligands
A common route to inferring the function of a protein is to
uncover its binding partners and then tap into the known
pathways and functional properties of the identified proteins.
There is no shortage of identified candidate PrPC-interacting
proteins (a list of over twenty identified ligands is given in
Table 1)— the main problem has been the inability of different
labs to uncover the same ligands and to prove functional
relevance of the binding proteins in in vivo assays. It seems
likely that some of the putative binding partners only bind to
PrPC in either in vitro systems or as a result of protein over-
expression since differences in compartmentalization should
occlude binding of the two proteins within a cell under normal
conditions (i.e. Bcl-2 and Grb-2, both of which are cytoplasmic
proteins) [99,100]. That being said, there has been considerable
debate surrounding the toxicity of PrP, either targeted directly to
the cytoplasm or for molecules which have undergone retro-
translocation from the ER into the cytoplasm. Some labs have
found that cytoplasmic PrP is toxic [101,102] whereas others
have failed to confirm this finding [103–105]. A recent paper
has suggested that under conditions of proteasomal inhibition,
cytoplasmic PrP co-aggregates with Bcl-2, a process which
correlates with toxicity [102]. Thus Bcl-2 may be an authentic
ligand for cytosolic PrP. Other ligands may be veritable PrPC-
interacting proteins but have not been demonstrated to
modulate either the biochemistry of PrPC or disease pathogen-
esis involving PrPSc. Two putative ligands which have received
much attention are the 37-kDa/67-kDa laminin receptor [106]
and the neural cell adhesion molecule (N-CAM) [107]. The
laminin receptor has been reported to act as a cellular receptor
for PrPC and for PrPSc and a requisite for PrPSc propagation in
infected neuronal cell lines [108–110]. However, the in vivo
relevance of the laminin receptor to prion biology and scrapie
pathogenesis remains obscure but the existence of laminin
receptor ‘knock-down’mice [111] may help to clarify this issue.
One possible role of the laminin receptor is as an intestinal
receptor for ingested prions [112]. Indeed, blocking the laminin
receptor with antibodies prevented the uptake of bovine prions
by enterocytes [113]. The PrPC/N-CAM interaction was un-
covered in N2a neuroblastoma cells without protein over-
expression using mild formaldehyde crosslinking, a technique
which can lock together protein complexes which may only be
transiently associated [107]. PrPC is capable of binding to all
three splicing isoforms of N-CAM. This interaction has been
confirmed using in vivo crosslinking in the brains of wild-type
Table 1
Proteins and molecules which have been reported to interact with PrPC or PrPSc
PrPC-interacting protein Sub-cellular localization Method of discovery Binding epitope on PrPC Reference(s)
GFAP Cytoplasmic
(cytoskeleton)
Ligand blots Unknown [169]
Bcl-2 The cytoplasmic
face of organelles
Yeast 2-hybrid Residues 72–254 [99]
Grb2 Cytoplasmic Yeast 2-hybrid N-terminal and C-terminal
binding sites
[100]
Synapsin-1b Synapse Yeast 2-hybrid N-terminal and C-terminal
binding sites
[100]
Pint1 Unknown Yeast 2-hybrid Residues 90–231 [100]
Glycosaminoglycans
(i.e. heparin)
Cell membrane,
extracellular matrix
Heparin-agarose pull-down on
PI-PLC-treated cells
Residues 23–52, 53–93,
and 110–128
[170,171]
Caveolin Caveolae
(cell membrane)
Co-purification in N2a cells Unknown [172]
Dystroglycan Cell membrane
(transmembrane)
Co-immunoprecipitation Unknown [173]
Synaptophysin Synaptic vesicles
(transmembrane)
Co-immunoprecipitation Unknown [173]
Neuronal nitric oxide synthase
(nNOS)
Peripheral membrane
protein
Co-immunoprecipitation Unknown [173]
ApoE a Secreted Co-immunoprecipitation/pull-downs with
recombinant proteins
Residues 23–90 [174]
Plasminogen Secreted Immobilized serum proteins probed with
PrPC- or PrPres-containing material
Binds to both PrPC and
PrPres (PrP27–30)
[121,125]
ER Chaperones (calnexin,
calreticulin, protein disulfide
isomerasea, BiPa, grp94)
Endoplasmic reticulum Two sets of immunoprecipitations on
radio-labeled cells
Unknown [175]
Hsp60 Mitochondria Yeast 2-hybrid Residues 180–210 [176]
NRAGE Cytoplasm and
peripheral membrane
protein
Yeast 2-hybrid Residues 122–231 [177]
TREK-1 Cell membrane
(transmembrane)
Bacterial 2-hybrid Residues 128–230 [178]
Rdj2 Cytoplasmic face
of membranes
In vitro pull-downs with GST fusions Unknown [179]
Tubulin Microtubules Chemical crosslinking Unknown [180]
αB-crystallin Cytoplasm Yeast 2-hybrid Unknown [181]
ZAP-70 Cytoplasm Co-immunoprecipitation Unknown [182]
Fyn Cytoplasmic face
of membranes
Co-immunoprecipitation Unknown [182]
Casein kinase 2 α/α′ subunits Cytoplasmic Far-Western blots and plasmon resonance
using recombinant proteins
Residues 105–242 [183]
Nrf2 Cytoplasm/nucleus Alkaline phosphatase-PrPC fusion used to
screen a mouse brain cDNA library
Unknown [184]
APLP1 Cell membrane Alkaline phosphatase-PrPC fusion used to
screen a mouse brain cDNA library
Unknown [184]
RNA aptamers N/A GST-PrPC fusion and library of RNA
sequences
N-terminus
(residues 23–52)
[185]
Laminin Secreted Recombinant GST-PrPC and laminin
co-purification
Unknown [186]
37-kDa/67-kDa laminin
receptor
Cell membrane Yeast 2-hybrid Residues 144–179
(direct) and residues
53–93 (heparan sulfate
proteoglycan-dependent)
[106,187]
Stress-inducible protein 1 Cytoplasm Complementary hydropathy Residues 113–128 [118]
N-CAMa Cell membrane Mild formaldehyde crosslinking in N2a cells Residues 141–176 [107]
‘Protein X’
(hypothetical protein)
Unknown Inferred from prion inoculations in transgenic
mice expressing chimeric human/mouse PrPC.
Discontinuous epitope
comprising residues
167/171 and 214/218
[188,189]
a PrPC-interacting proteins which were also found in an in vivo study employing time-controlled transcardiac perfusion crosslinking of wild-type mice brains [114].
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shown to be physiologically relevant (although not to disease
pathogenesis since N-CAM knockout mice have unalteredprion incubation times [107]). Santuccione et al. have shown
that PrPC can recruit N-CAM to lipid rafts where it participates
in the activation of Fyn kinase [115] (interestingly, signal
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previously been documented [116], although genetic ablation
of Fyn in mice has no significant effect on prion disease
pathogenesis [117]). Furthermore, interactions between PrPC
and N-CAM are involved in neurite outgrowth. Thus, N-CAM
may represent one of the more physiologically plausible PrPC
-interacting proteins identified to date. Another noteworthy
putative PrPC-interacting protein is stress-inducible protein 1
(STI1) [118]. Recombinant STI1 and a peptide comprising the
PrP-binding site on STI1 were both capable of decreasing cell
death in retinal explants following treatment with the protein
synthesis inhibitor anisomycin. No protective activity was
observed with Prnp0/0 mice suggesting that STI1 binding to
PrPC mediates the neuroprotection. ST1I/PrPC-dependent
neuritogenesis and neuroprotection were dependent on mito-
gen-activated protein kinase and protein kinase A pathways,
respectively [119]. Another study has found that the STI1-PrPC
interaction is involved in regulating superoxide dismutase
activity [120]. One final interacting protein of note is
plasminogen, a zymogen precursor to a serine protease present
in serum. Plasminogen was first reported to interact specifically
with disease-associated forms of PrP (PrP27–30 and PrPSc) [121]
although subsequent studies have shown that it is also capable
of interacting with PrPC [122,123]. This interaction is likely
mediated by the kringle domains present in plasminogen [124].
Binding of PrPC to plasminogen stimulates both tPa-mediated
activation of plasminogen [125,126] and cleavage of PrPC
[127]. In vivo studies have shown that plasminogen deficiency
has no major effect on disease progression or survival in prion-
inoculated mice [128] and does not alter endoproteolytic
processing of PrPC [129].
In an attempt to accurately define the PrPC ‘interactome’ in
the brain, Schmitt-Ulms and co-workers developed a novel
technique (termed time-controlled transcardiac perfusion cross-
linking (tcTPC)) which uses mild formaldehyde crosslinking to
lock together protein complexes followed by immunoaffinity
purification of the target protein and the identification of
binding partners by mass spectrometry [114]. The validity of
this technique was verified by isolating other known members
of the γ-secretase complex (which is of relatively low
abundance) using one component as the subject for immunoaf-
finity chromatography. Using this same approach for PrPC,
several candidate interacting proteins were uncovered, includ-
ing various splicing isoforms of N-CAM and the amyloid
precursor protein (APP). Some of the identified proteins may
have been “pulled down” solely because of their proximity to
PrPC in the membrane and their abundance, and may not
actually interact with PrPC in a phenotypically significant
manner. However, further application of this technology may
ultimately reveal the proteins to provide insights into PrPC (and
PrPSc) physiology.
No ligand for Doppel has surfaced thus far (although there
are contradictory reports concerning the ability of Doppel to
bind to the 37-kDa/67-kDa laminin receptor [130,131]). Unlike
PrPC, Doppel is unable to bind to either Grb-2 or GFAP in a
two-hybrid assay [132]. In addition, a large-scale yeast two-
hybrid screen failed to find a Doppel-interacting protein from ahuman ORF cDNA library [133]. In an interesting report,
fusions of either Doppel or PrPC to the Fc portion of IgG bind to
the granule cell layer of the cerebellum, suggesting the
existence of a cerebellar protein which may mediate Doppel
toxicity [134]. The discovery of a common ligand for PrPC and
Doppel would be immediately useful for dissecting the
pathways involved in genotypic interactions between Prnp
and Prnd (see below). No binding partner for Shadoo has yet
been unearthed, although it will be of interest to look for a
potential interaction between Shadoo and stress-inducible
protein 1 since its binding epitope in PrPC is well-conserved
in Shadoo [118].
6. Doppel and Shadoo in prion infections
The necessity of PrPC expression for the occurrence of prion
disease and the propagation of prions has been well documented
[6,7]. In contrast, several lines of evidence suggest that Doppel
is neither required for prion pathogenesis nor is capable of
modulating the disease process. Transgenic mice expressing
Doppel in the CNS on a wild-type PrP background have
unaltered disease incubation times and pathological lesion
profiles upon challenge with infectious prions [135]. Secondly,
no differences in either disease incubation time, vacuolation
profiles, patterns of neuronal loss, or PrP deposition were
observed between Rcm0 (which over-express Doppel) and Npu
(which do not over-express Doppel) Prnp0/0 mice crossed with
mice expressing PrP when inoculated with prions [136]. In
humans, Doppel expression is unchanged in patients with
sporadic CJD and no changes in murine Doppel expression
between uninfected and infected N2a cells have been found
[92]. Furthermore, expression of Doppel in infected cells does
not modify toxicity, and there are as yet no indications of
abnormally folded forms of the protein. One hypothesis as to
why Doppel is unable to adopt a β-sheet enriched structure is
that its second disulfide bridge imparts added stability, making
the transition highly thermodynamically unfavourable. Whyte
et al. looked into this possibility by creating a Doppel mutant
with a single disulfide bridge, analogous to the structure of PrPC
[137]. This mutant was indeed less stable, but the stability of
wild-type Doppel was less than wild-type PrPC, suggesting that
thermodynamic instability alone is not sufficient to explain the
inability of Doppel to undergo a conformational transition. No
evidence of an α to β transition (even if β-rich recombinant PrP
was present) was observed for either wild-type or single
disulfide-mutant Doppel [137]. In a yeast two-hybrid setting,
Doppel was incapable of interacting with itself [130], possibly
indicating an inability to undergo dimerization or multimeriza-
tion steps that are associated with conformational conversion
and templated refolding (however, this conclusion is tempered
by the caveat that fusion proteins expressed in the reducing
environment of the yeast cytosol do not acquire the disulfide
linkages and glycosyl modifications found in the mature
mammalian proteins). When added to the observation that
Doppel does not accumulate to appreciable amounts in the brain
of adults, these results suggest that Doppel is not involved in
prion disease. While investigations into the potential role of
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processes of pyramidal cells in the hippocampus, represent a
major site of Shadoo expression and comprise one of the earliest
clinical target areas in several varieties of prion disease in
rodents [138,139]. Accordingly, we have speculated that PrPSc
might interfere in trans with a Shadoo-dependent pathway
resulting in abnormalities in dendritic spines. Also, it will be
interesting to see if Shadoo is itself directly involved in prion
disease biology, since the hydrophobic tract shared between
PrPC and Shadoo corresponds to epicenter of misfolding to
PrPSc.
7. Doppel and PrP in knockout and transgenic mice
Other than its aforementioned role in the male reproductive
system, the majority of interest in studying the Doppel protein
has stemmed from its neurotoxic properties when present in the
brains of Prnp0/0 mice [15,28,135]. This effect is either
completely blocked or significantly reduced upon co-expression
of PrPC, implying either a direct interaction between the two
proteins or the existence of shared binding partners. Under-
standing the biology of this paradigm is important for other
areas in prion research since 1) The ability of PrPC to block the
pro-apoptotic activity of Doppel hints at its cellular function and
detailed studies using this paradigm may help to elucidate the
enigmatic function of PrPC and 2) The pro-apoptotic activity of
Doppel may partly mimic the action of PrPSc and thus may be
useful for deciphering the molecular events underlying prion
disease pathogenesis. Information acquired to date can be
summarized as follows.
7.1. Doppel in Prnp0/0 and transgenic mice
As mentioned earlier, discovery of the Prnd gene and the
Doppel protein was hastened by a need to explain phenotypic
discrepancies between various strains of Prnp0/0 mice. These
data have been discussed at length previously (Table 2)
[15,27,28,140] leading to the conclusion that ectopic Doppel
expression rather than loss of PrPC is the underlying cause of
phenotypic variation (presence or absence of a cerebellar ataxia
syndrome). Indeed, an increase in Doppel protein expression
can be seen in the brains of Rcm0 mice [60] and immunohis-
tochemical analyses on the brains of Ngsk and Rcm0 mice haveTable 2
Characteristics of strains of Prnp0/0 Mice
Strain Knockout strategy Dele
splic
ZrchI Replacement of PrP residues 4–187 with a neo cassette No
NPU Insertion of a neo cassette following residue 93 of PrP No
Ngsk Replacement of a region containing 0.9 kb of Prnp intron 2,
the entire ORF, and 0.45 kb of the 3′ UTR with a neo cassette
Yes
Rcm0 Replacement of a region containing 0.9 kb of Prnp intron 2,
the entire ORF, and 0.45 kb of the 3′ UTR with a HPRT cassette
Yes
ZrchII Replacement of 0.27 kb of intron 2 to 0.6 kb following exon 3
with a loxP site
Yes
Rikn Replacement of a portion of intron 3, the entire ORF,
and a portion of the 3′ UTR with a neo cassette
Yesdemonstrated Doppel expression in the cerebellum [135]. An
elegant proof of this concept was achieved by meiotic deletion
of the Prnd gene in ZrchII Prnp0/0 mice which are ataxic and
have Purkinje cell loss [141]. No pathology was observed in
these mice, confirming that the phenotypic defects in ataxic
strains of Prnp0/0 mice result from expression of Doppel and
not the loss of PrPC function or the cis-activation of genes
adjacent to the Prn gene complex. Interestingly, cerebellar
Doppel in Ngsk Prnp0/0 mice was associated with a distinct
molecular signature on Western blots but further tests using
independent antibodies and other strains of mice are required to
validate this observation [142].
ZrchII Prnp0/0 mice have an ataxic phenotype with loss of
Purkinje cells and the age of onset is inversely related to the
level of ectopic Doppel expression. Hybrid ZrchI/ZrchII mice
(with only a single copy of the Doppel-producing ZrchII
allele) develop disease at a later age whereas mice with two
copies of the ZrchII allele and also expressing a cosmid
containing the Prnd and Prnp genes but in which the PrP open
reading frame has been replaced by the tetracycline transacti-
vator express higher levels of Doppel and develop disease at
an earlier age [28]. The ataxic phenotype and Purkinje cell
degeneration could be rescued in the progeny of crosses with
tga20 mice (over-expressing PrPC), even though the transgene
promoter elements in tga20 mice do not drive PrPC expression
in Purkinje cells. These data prompt two possible interpreta-
tions: (1) PrPC is able to counteract in trans (in a cellular
sense, akin to paracrine action) a Doppel-dependent molecular
event occurring in Purkinje cells (i.e. by virtue of PrPC
expression in CGNs) or (2) the critical event occurs in CGNs
expressing Doppel and the consequent dysfunction (but not
necessarily degeneration) causes Purkinje cell loss via an
indirect mechanism (e.g., by loss of a hypothetical trophic
signal emanating from CGNs); in this scenario, PrPC in CGNs
expressed from the tga20 transgene array would directly block
Doppel toxicity.
Transgenic mice expressing Doppel under control of the
hamster Prnp promoter superimposed on a ZrchI Prnp0/0
genetic background (non-ataxic, non-Doppel over-expressing)
develop ataxia and have profound loss of cerebellar granular
neurons (CGNs) and Purkinje cells (for summary of Doppel
and ΔPrP transgenic mice, see Table 3) providing additional
support for the causal relationship between Doppel expressiontion of Prnp exon 3
e acceptor site?
Late-onset
ataxia?
Up-regulation of
Doppel in the brain?
Reference(s)
No No [4]
No No [8]
Yes Yes [27]
Yes Yes [15]
Yes Yes [28]
Yes Yes (in cell lines derived
from the hippocampus)
[140]
Table 3
Summary of transgenic mice expressing doppel or ΔPrP
Transgenic line Promoter/transgene construct Transgene expression Phenotype(s) Rescue by PrPC? Reference(s)
PrPΔ32–93
(PrPΔC)
Murine Prnp ‘minigene’
construct
Neuronal
(no Purkinje cells)
– N/A [54]
PrPΔ32–106
(PrPΔD)
Murine Prnp ‘minigene’
construct
Neuronal
(no Purkinje cells)
– N/A [54]
PrPΔ32–121
(PrPΔE)
Murine Prnp ‘minigene’
construct
Neuronal
(no Purkinje cells)
Ataxia with CGN degeneration Yes [54]
PrPΔ32–134
(PrPΔF)
Murine Prnp ‘minigene’
construct
Neuronal
(no Purkinje cells)
Ataxia with CGN degeneration Yes [54]
L7-PrPΔ32–134 L7 promoter Purkinje cells Ataxia with Purkinje cell loss Yes (some Purkinje cell loss apparent) [145]
Tg(Dpl) Syrian hamster Prnp
promoter
Neuronal Ataxia with CGN degeneration
and Purkinje cell loss
Yes (limited degeneration in
high-expresser lines)
[135]
L7-Dpl L7 promoter Purkinje cells Ataxia with Purkinje cell loss Yes (low-expressing lines only) [143]
Tg-N(Dpl) NSE promoter Neuron-specific Ataxia with Purkinje cell loss Yes (Prnp+/+ only) [144]
Tg-P(Dpl) PCP-2 promoter Purkinje cells Ataxia with Purkinje cell loss Yes (Prnp+/+ only) [144]
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remain apparently healthy at the time that cerebellar
pathology develops and despite the presence of high levels
of Doppel expression, arguing that a CGN- or Purkinje cell-
specific co-factor or Doppel-binding protein hastens the
neurodegenerative phenotype. In agreement with the afore-
mentioned studies on ZrchII mice, age of onset of ataxia was
inversely correlated with Doppel protein levels. Phenotypic
rescue could be achieved by crossing the mice to mice over-
expressing hamster PrPC (Tg(SHaPrP+/+)7/Prnp0/0-ZrchI)
although one line expressing Doppel at a high level still
exhibited some neurodegeneration in the cerebellar cortex, in
agreement with other studies in which high levels of Doppel
expression were unable to be counteracted by PrPC expres-
sion [143].
Transgenic mice expressing Doppel specifically targeted to
Purkinje neurons results in ataxia and Purkinje cell loss,
followed later by granule cell reduction and gliosis (which the
authors attribute to a distinct mechanism stemming from
Purkinje cell death) confirming that Doppel expression is
toxic to Purkinje cells [143]. Only mice expressing lower levels
of Doppel could be rescued from the ataxic phenotype by co-
expression of PrPC (and even in this case, some late onset
Purkinje cell loss was apparent); mice expressing high levels of
Doppel on either a wild-type Prnp background or a tga20
transgenic (mouse PrPC over-expressed from the Prnp ‘mini-
gene’ construct) background exhibited severe ataxia and
cellular loss. These results imply that PrPC is unable to
counteract the deleterious effects of high levels of Doppel
expression. A separate report has confirmed that Purkinje cell-
specific expression of Doppel (as well as neuron-specific
expression controlled by the neuron-specific enolase (NSE)
promoter) is sufficient to confer ataxia and Purkinje cell
degeneration [144]. Again, age of onset was inversely related to
levels of Doppel. A single copy of wild-type PrP was able to
delay, but not prevent the ataxic phenotype. In this system, no
ataxia was observed in any Doppel-expressing line on a wild-
type Prnp+/+ background.
The phenotypic defects seen in mice ectopically expressing
Doppel in the brain are reminiscent of an earlier-describedartificially-induced disease (‘Shmerling syndrome’) in trans-
genic mice expressing N-terminally truncated PrP molecules
[54]. Mice expressing PrPΔ32–121 or PrPΔ32–134 (collec-
tively referred to as ΔPrP) but not PrPΔ32–93 or PrPΔ32–
106 develop ataxia characterized by degeneration of cerebel-
lar granule cells. As is the case for Doppel, this phenotype is
only apparent when the mutant PrPs are expressed on a
Prnp0/0 background demonstrating that the process can be
abrogated by wild type PrPC. Similar to Doppel, Purkinje-cell
specific expression of ΔPrP is also sufficient to induce ataxia
and Purkinje cell loss in a manner that is dependent on the
presence of wild-type PrP [145]. Two recent studies which
utilize transgenic mice expressing more restricted deletions on
a Prnp0/0 background have shown that deletions in the PrPs
central domain (in the form of either Δ94–134 [146] or
Δ105–125 [147]) are sufficient to cause ataxia and cerebellar
granule cell degeneration. Remarkably, toxicity is greatly
enhanced in these mice compared to mice expressing the
longer Δ32–121 and Δ32–134 deletions, pointing to the
central domain of PrP (and in particular the hydrophobic
tract) as the major determinant of this phenomenon. The
structural similarities between Doppel and ΔPrP certainly
suggest the economical explanation that the two diseases are
caused by a single mechanism [58]. One problem in positing
a single pathogenic pathway, however, has been the
differences in target cell populations in the cerebellum (i.e.
Purkinje cells vs. cerebellar granular cells vs. both types of
cell) amongst the various strains of mice. Although trivial
explanations are possible (i.e. differences in expression owing
to the use of different transgenic cassettes, different genetic
backgrounds), alternate explanations could involve trans
interactions between Purkinje neurons and CGNs with respect
to Doppel or ΔPrP and a loss of trophic factors (as previously
mentioned). However, other possibilities include binding of
Doppel/ΔPrP to different splicing isoforms within a hypothe-
tical protein ligand family.
Transgenic expression of either ΔPrP or Doppel also results
in a late-onset white matter pathology characterized by axon
and myelin degeneration implying a shared mechanism of
white matter toxicity between the two structurally similar
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transgenic mice expressing PrP alleles with central domain
deletions [146,147]. Expression of PrPC under control of an
oligodendrocyte-specific promoter rescued the axon–myelin
degeneration and enhanced survival but did not abrogate the
cerebellar pathology. In contrast, neuronal-specific PrPC
expression conferred partial resistance to the ΔPrP-induced
cerebellar pathology and increased survival but had no effect
on the axon–myelin degeneration. These experiments point to
a role for PrPC in the maintenance of myelin integrity and is
supported by the observation that demyelination occurs in the
spinal cord and peripheral nerves of aged ZrchI Prnp0/0 mice
[149].
7.2. Cellular models and Prnp/Prnd interactions
Some investigators have sought to create cellular models
of Doppel/ PrPC genetic interactions. In one strategy, primary
CGNs – a target of Doppel/ΔPrP toxicity in vivo in
transgenic mice – are cultured from Prnp0/0 mice and
transfected with constructs encoding Doppel and PrP alleles
of interest. CGNs transfected with Doppel exhibit a
significant increase in apoptotic events and levels are returned
to baseline upon co-transfection with wild-type PrPC [84]. In
agreement with the observations in transgenic mice, no
increase in apoptosis was observed when CGNs isolated from
wild-type (Prnp+/+) mice were utilized. This model system
has appeal because it utilizes differentiated neurons and not
immortalized cells, although it suffers from the typical
inability to obtain high transfection rates in primary cultures.
A second strategy involves serum deprivation of a hippo-
campal cell line derived from Doppel-expressing Rikn Prnp0/0
mice [150]. Following serum deprivation, Prnp0/0 cells die
via apoptosis (and have shorter neurite extensions) whereas
Prnp+/+ cells or Prnp0/0 cells transfected with PrPC remain
healthy. These cells express Prnp/Prnd chimeric mRNAs and
low amounts of Doppel protein [151]. Serum deprivation-
induced toxicity is moderately enhanced in cells expressing
additional amounts of Doppel and toxicity is blocked in the
presence of wild-type PrPC. However, there is some doubt as
to whether serum-induced apoptosis in Prnp0/0 cells is
additive in a pathologic sense to Doppel over-expression,
since serum deprivation of cells prepared from a strain of
Doppel non-expressing Prnp0/0 mice (ZrchI) also induces
apoptosis [151]. A third model in a recently-published study
has provided evidence that N2a cells (a popular cell line for
studying prion replication) can be sensitized to Doppel
toxicity following depletion of endogenous PrPC using
RNA interference [152]. A separate strategy is to add purified
recombinant Doppel (rDpl) to neuronal cells. Qin et al. have
shown that rDpl is capable of inducing caspase-3 activation
when added to either N2a cells or primary rat adult reactive
astrocytes following transfection with PrP RNAi [152].
Addition of rDpl to cultures of Prnp0/0 CGNs also causes
apoptosis, but this effect is also apparent in Prnp+/+ wild-type
mice casting doubt on its relevance to in vivo phenotypes
[84].7.3. Protein structural determinants and Prnp/Prnd
interactions
In an attempt to characterize the domains in Doppel and PrPC
responsible for eliciting the neurotoxic or neuroprotective
activity, respectively, several investigators have utilized a
mutagenesis approach. The rescue of Doppel-induced cerebellar
degeneration by PrPC requires an intact N-terminal domain of
PrPC. Transgenic mice expressing PrPΔ23–88 on the ataxic
Ngsk Prnp0/0 background develop ataxia and Purkinje cell loss
indistinguishable from non-transgenic littermates suggesting
that the octarepeat region is required for neuroprotection [153].
In agreement with these results, PrP alleles lacking either the
charged N-terminal region (Δ23–28) or the octarepeats (Δ51–
90) also failed to rescue Doppel-induced apoptosis in primary
cultures of Prnp0/0 cerebellar granule cells [84]. In contrast,
rescue of ΔPrP toxicity could be achieved by co-expression of
PrPΔ32–93 in transgenic mice [154], perhaps pointing to the
existence of subtle differences in the mechanisms of Doppel and
ΔPrP toxicity or the necessity of residues 23–31 of PrP for
neuroprotection. Fusion of PrPC residues 1–124 but not
residues 1–95 to the N-terminus of Doppel protected cells
from Doppel toxicity during serum deprivation implicating
residues 96–124 in the neuroprotective function of PrPC [155]
and this region contains a portion of the highly conserved
hydrophobic domain. In agreement with this data, PrP lacking
residues 95–132 was incapable of inhibiting serum deprivation-
induced apoptosis whereas a 124–146 deletion retained this
ability reinforcing the importance of the region between
residues 95–123 for neuroprotection [151]. Interestingly, a
deletion encompassing the octarepeats actually enhanced
toxicity in this paradigm. A role for copper binding in PrP
neuroprotection is implied from analyses of PrP alleles lacking
the copper-binding sites in the octarepeats, which proved to be
non-protective [84], although this has not yet been established at
the level of physical PrP/Cu2+ interactions in vivo, and also
because one or two other copper binding sites still exist in this
construct. Collectively, these results show that various regions
of the N-terminus of PrPC are important for maintaining its
neuroprotective activity. Several of these regions (residues 23–
28 and the octarepeats) have been implicated in the proper
trafficking of PrPC [49,55] suggesting that their deletion may
prevent PrPC from localizing with a required co-factor.
Mutagenesis experiments have shown that the helix B/B′
region of Doppel (residues 101–125) are required for Doppel-
induced toxicity in cultured Prnp0/0 neurons [84]. Notably, this
is a region of structural deviation from PrPC, suggesting that
altered binding to an essential co-factor might alter the
experimental endpoint.
7.4. Cellular mechanisms in Prnp/Prnd interactions
The downstream events initiated by CNS expression of
Doppel or ΔPrP and culminating in loss of cerebellar cells
remain enigmatic. Any proposed mechanism must take into
account the ability of PrPC to rescue the Doppel-induced
toxicity. Several scenarios have been proposed including (1)
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copper) required by Doppel to activate an apoptotic pathway;
(2) direct competition for a shared ligand required by Doppel to
subvert a cellular pathway required for cell viability; (3)
triggering of opposing neurotoxic and neuroprotective path-
ways by Doppel and PrPC, respectively; (4) direct binding of
PrPC to Doppel prevents it from eliciting its toxic effect; (5)
increased free radicals arising from Doppel expression cause
oxidative damage to membranes or proteins with PrPC
antagonizing this effect and (6) PrPC interfering with the
formation of ER or plasma membrane multimeric pores
composed of Doppel (for a complete pictorial representation,
see [156]). The potential existence of a common neurotoxic
mechanism used by both Doppel and mutant forms of PrP in
genetic prion disease has been proposed based on the fact that
several mutations in PRNP which cause genetic CJD (such as
E200K) result in amino acid shifts within the α-helical domain
to residues conserved in Doppel [157]. Thus, these substitutions
may result in a PrP protein capable of mimicking Doppel,
leading to neurotoxic events.
Although the Prnp and Prnd genes “interact” in CNS
toxicity assays, this is not to say that there are physical
interactions between their cognate protein products. Indeed,
given that neither PrPC nor Doppel have been suggested to exist
as dimers in vivo, physical interactions are not necessarily
expected. Accordingly, there is little evidence of a direct
interaction between Doppel and PrPC [130,158]. Nonetheless,
binding of recombinant Doppel to recombinant PrPC was
observed in one study and was inhibited by pre-incubation of
Doppel with a PrP106–126 peptide [159] and co-purification of
Doppel and bands that appear to be endogenous mono- or un-
glycosylated PrPC was achieved in vitro in N2a cells by using a
TAP-tagged Doppel construct as bait [152,160]. Doppel and
PrPC co-localize on the surface of transfected human and mouse
neuroblastoma cells implying proximity of the two proteins in
the plasma membrane [152], whereas Doppel and PrPC may not
inhabit the same membrane microdomains in testis [61] —
perhaps a neuron-specific co-factor is involved in the interac-
tion. Again, however, co-localization as determined by light
microscopy certainly does not automatically confirm a physical
interaction. An indirect interaction between Doppel and PrPC is
implied by studies in which antibodies to either single protein
induce co-internalization of both proteins [160]. Despite these
observations, co-immunoprecipitation of wild type Doppel and
PrPC (a simple point of reference for confirming stable protein–
protein interactions) has never been achieved, although it is
possible to invoke a caveat that the proper detergent conditions
were not implemented. Additionally, in a yeast 2-hybrid setting
Doppel fails to interact with PrPC [130].
With regards to possible downstream pathways initiated by
Doppel, cultures of Prnp0/0 cerebellar granule neurons die via
an apoptotic pathway upon exposure to transfected Doppel as
demonstrated by activation of caspase-3 [84]. In addition, PrP-
depleted N2a cells expressing Doppel also exhibit caspase-3
and caspase-10 (but not caspase-9) activation [152]. These
studies clearly demonstrate that Doppel somehow engages a
pro-apoptotic pathway (interestingly, minute amounts of PrPScadded to tissue culture cells also induces apoptosis in a caspase-
12-dependent manner [161]). Caspase-3 and TUNEL-positive
cerebellar granule neurons are also observed in the brains of
mice expressing PrPΔ105–125 [147], perhaps suggesting a
common route of toxicity for both Doppel and N-terminally
deleted forms of PrP. Crossing mice expressing a toxic
PrPΔ32–134 allele with mice lacking Bax (a pro-apototic
protein which is an important regulator of neuronal death in the
CNS) has shown that although Bax deletion can delay clinical
illness and suppress cerebellar granule neuron loss in young
mice, it does not reduce white matter pathology or age of death
[162]. Similarly, Bax deletion has no effect on the progression
of prion disease in inoculated mice [163]. These experiments
suggest that apoptotic proteins other than Bax are likely
involved in mediating Doppel/ΔPrP toxicity. In support of the
apoptosis mechanism, studies in Chinese Hamster Ovary cells
have pointed to perturbations in subplasma membrane, ER, and
mitochondrial calcium pools upon expression of either PrPC or
Doppel [164]. In general, PrPC and Doppel elicit opposing
effects associated with protective and apoptotic calcium
signaling, respectively, whereas co-expression results in a
counter-balancing neutral effect. There is some evidence that
Doppel causes oxidative damage to the brain and cultured cells
from Prnp0/0 mice. Rcm0 Prnp0/0 mice were reported to have
increased expression of heme oxygenase 1 and nitric oxide
synthase, and increased levels of nitrite, protein oxidation,
nitrotyrosine, and lipid peroxidation, all pointing to an increase
in oxidative stress in Doppel-expressing mice [165]. In
comparison, no changes in either nitrotyrosine or in modifica-
tion of carbonyl groups (both markers of oxidative damage)
were found in other transgenic mice expressing Doppel [97].
A recent report has demonstrated that PrPC and Doppel are
sorted differently in cultured Madin–Darby canine kidney cells
[158]. Doppel is typically found on the apical surface whereas
PrPC is found on the basolateral side. Interestingly, co-
expression of Doppel and PrPC directs PrPC to the apical
side, putting PrPC into the vicinity of Doppel and possibly
providing a mechanism by which PrPC can abrogate Doppel
toxicity. Also, the hydrophobic tract of PrPC is necessary for
basolateral sorting and can confer basolateral sorting to Doppel
in a dominant manner. Of further interest is the observation that
a pathogenic PrP mutation (the AV3 hydrophobic mutation
which induces the CtmPrP topology and causes neurodegenera-
tion [52]) causes PrPC to be sorted apically.
7.5. A molecular model for Prnp/Prnd interactions
One model has been proposed which attempts to explain
interactions between Doppel and PrPC in terms of an
unidentified prion protein receptor termed LPrP or Tr. In this
model, PrPC binds to LPrP and elicits an unknown “positive”
signaling event favouring cell survival (Fig. 3) [14,54,
146,147]. In the absence of PrPC, Doppel (or ΔPrP) also
binds to LPrP but lacks the effector domain (which is present on
PrPC) to initiate positive signaling and instead either functions
as a dominant negative by blocking signaling or initiates
‘improper signaling’ through LPrP. PrP
C has a higher affinity
Fig. 3. The LPrP model of functional interactions between prion proteins in transgenic mice. (a) In wild-type (Prnp+/+) mice, PrPC binds to a hypothetical ligand (LPrP)
and initiates an as-yet-unidentified signaling event favouring cell survival. This binding event could occur either in cis or trans configurations. Two binding sites for
LPrP on PrP
C are implied— a C-terminal anchoring site and an N-terminal effector site which enables signaling. (b) In Prnp0/0 mice, a hypothetical PrPC-like protein,
π, binds to LPrP and initiates the signaling event in the absence of PrP
C. π shares in common with PrPC the N-terminal effector domain and can therefore elicit signaling
activity through LPrP. (c) When Doppel orΔPrP bind to LPrP in Prnp
0/0 mice, ‘improper’ signaling is initiated resulting in cellular death since both proteins lack the N-
terminal effector domain required for pro-survival signaling. (d) When Doppel orΔPrP are expressed in Prnp+/+ mice, PrPC possesses higher affinity for LPrP and thus
prevents or reduces Doppel/ΔPrP binding.
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block initiation of the toxic phenotype. No candidates for LPrP
have come forward, but the following characteristics are
predicted based on the current model: (1) Expression in the
CNS with particular localization in the Purkinje cells or
cerebellar granule cells. (2) Two binding sites for PrPC: one
not present in Doppel which acts as an effector domain and a
second which is shared between the two proteins and (3) a
cytoplasmic domain (or the ability to interact with another
protein with cytoplasmic sequences) which can initiate down-
stream signaling. It seems plausible that altered binding to LPrP
could also explain the toxicity of CtmPrP. Because the
hydrophobic tract of CtmPrP is embedded in the membrane,
the remaining cell surface-exposed portion of PrP may
structurally resemble ΔPrP (in particular PrPΔ32–134),
which could bind LPrP in a manner reminiscent of ΔPrP and
induce a similar phenotype. In support of this idea, transgenic
mice expressing a PrP mutant which generates increased
amounts of CtmPrP develops a neurological illness charac-
terized by a progressive loss of cerebellar granule neurons
[166]. However, toxicity is dependent on the presence of wild-type PrPC, which is unlike the case of ΔPrP in which PrPC
must be absent for toxicity to occur. An intriguing question is
whether or not LPrP (or a similar protein) may play a role in
prion disease. Indeed, the presence of a transmembrane protein
which transduces neurotoxic signals emanating from PrPSc has
been postulated based on studies of transgenic mice expressing
PrP lacking the GPI anchor [167]. Following prion inoculation,
these mice have abundant PrPSc-containing plaques and
protease-resistant PrP but never develop clinical prion disease
[168] suggesting that PrPSc binding to a component of the cell
membrane is essential for eliciting neurodegeneration.
Another facet of the above model is a hypothetical prion-like
protein termed ‘π’ which was invoked to explain the lack of a
phenotype in Prnp0/0 mice. π also binds to LPrP and can initiate
the positive signaling event favouring cell survival. It has
recently been shown that like PrPC, the newest prion protein
family member, Shadoo, is capable of blocking Doppel-induced
apoptosis in Prnp0/0 CGNs (JCW and DW, in revision). Upon
removal of the hydrophobic domain, Shadoo loses its ability to
be neuroprotective in a manner similar to PrPC. Together with
shared biochemical properties between Shadoo and PrPC
667J.C. Watts, D. Westaway / Biochimica et Biophysica Acta 1772 (2007) 654–672mentioned above these observations underscore similarities
between Shadoo and the hypothetical π protein.
Lastly, while the above observations indicate incremental
progress towards molecular definitions (and expectations) for in
vivo PrPC partners, the cell biological premises of the working
model may need revision. Though originally framed in the
context of neurotrophic signaling between adjacent cells, this
framework is likely incorrect since (a) a groundswell of data
favours a role for PrP in response to exogenous toxic stimuli,
rather than endogenous neurodevelopmental processes and (b)
the antagonistic effects between PrP and Dpl or internally
deleted forms of PrP may occur in the same (i.e. co-transfected)
cells.
8. Conclusions and future directions
A current portrait of the prion protein family would include
three members: PrPC (and perhaps its alter-ego PrPSc), Doppel,
and the newest member, Shadoo. Investigations into the
functions of the three proteins have revealed similarities (PrPC
and Shadoo) and striking differences (PrPC and Doppel).
However, an economical and intuitively ‘correct’ molecular
description of prion protein function remains elusive and
solving the problem will likely involve sorting out in vivo wheat
from in vitro chaff with regards to interacting proteins. Phy-
siologically important binding interactions of prion proteins
may involve either weak or transient interactions, explaining the
difficulty encountered thus far in nailing them down. None-
theless, it is imperative that such interactions be defined so that
a better understanding of prion biology is achieved. In
particular, the events linking CNS Doppel/ΔPrP expression to
apoptosis and the presence of PrPSc to neuronal death remain
mysterious.
Although the study of the infectious aspects of prions
remains a priority, research efforts into the ‘normal’ biology of
prion proteins has merit, not least because these abundant
molecules do not fit into pigeon-holes defined for other families
of cell-surface proteins. Future goals in the cellular prion
biology field may include: (1) Identification of LPrP (or a similar
protein) which mediates Doppel-induced neurotoxicity and may
be relevant to both the in vivo pathogenesis of PrPSc and the
function of PrPC; (2) an undisputable identification of the
function of PrPC, perhaps stemming from subjecting Prnp0/0
mice (or even Prnp0/0/Sprn0/0 mice) to ‘stressful’ stimuli
required to unmask cryptic phenotypes; and (3) understanding
intracellular pathways initiated by cell-surface prion proteins in
both normal and diseased states.
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